Soluble PD-L1 reprograms blood monocytes to prevent cerebral edema and facilitate recovery after ischemic stroke
Jennifer E. Kim(Neurological Surgery), Christopher M. Jackson(Johns Hopkins University), Risheng Xu(Key Laboratory of Nuclear Radiation and Nuclear Energy Technology), Betty Tyler(Johns Hopkins University), Rafael J. Tamargo(Johns Hopkins University), Michael Lim(Stanford University), Ryan P. Lee(Johns Hopkins University), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Pavan P. Shah(Johns Hopkins University), Lyla Atta(Johns Hopkins University), Justin M. Caplan(Johns Hopkins University), Judy Huang(Johns Hopkins University), Jean Fan(Johns Hopkins University), Shenandoah Robinson(Kennedy Krieger Institute), James Feghali(Johns Hopkins University), Lauren L. Jantzie(University of New Mexico), Idan Levitan(Rabin Medical Center), Henry Brem(Johns Hopkins University), Nivedha Kannapadi(New York University), Zhipeng Hou(Johns Hopkins University), Eli Yazigi(Johns Hopkins University), L. Fernando Gonzalez(Johns Hopkins University), Kisha Patel(Johns Hopkins University), Adnan Bibic(Kennedy Krieger Institute), Ayush Pant(Stanford University), Raymond C. Koehler(Johns Hopkins University), Aanchal Jain(Johns Hopkins University), Eileen Kim(Johns Hopkins University)
Cited by 34
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k